Predicting resistance to targeted therapies in melanoma

Predicting resistance to targeted therapies in melanoma

Publication date: Nov 06, 2019

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, outlines how we might be able to predict resistance to targeted therapies in melanoma patients. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Concepts Keywords
Amsterdam Health
Barcelona Clinical medicine
Christian Medicine
Immunotherapy Immunotherapy
Melanoma Therapies melanoma
Mutation Cancer
Netherlands Melanoma
PhD Antineoplastic drugs
Receptor RTT
Ruff Targeted therapy
Spain Immunotherapy
Targeted Therapies Targeted immunotherapy

Semantics

Type Source Name
disease MESH melanoma
disease DOID melanoma
pathway BSID Melanoma
gene UNIPROT PDC
disease MESH Cancer
disease DOID Cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *